Nav: Home

Surgery timing after neoadjuvant chemoradiation in Stage IIIA NSCLC impacts OS

October 05, 2016

The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.

Approximately one third of all NSCLC patients have locally advanced (stage III, subtypes IIIA and IIIB) disease at the time of diagnosis, with a five-year survival ranging from 7 to 19%. Patients with stage III NSCLC represent a significant clinical challenge due to the poor prognosis associated with this stage of disease. Trimodality therapy involving the use of radiation concurrently with chemotherapy, otherwise known as neoadjuvant chemoradiation therapy (NCRT), followed by surgery is an acceptable treatment strategy for stage IIIA patients with resectable tumors and limited mediastinal node (N2) involvement. However, trimodality therapy has not been shown to have significant survival advantage over definitive chemoradiation therapy and the optimal interval to surgery (ITS) after completion of NCRT has not been well explored.

A group of investigators conducted a retrospective analysis to examine whether the ITS after completion of NCRT correlates with survival outcomes in clinical stage IIIA, T1-3 N2 NSCLC patients using patient records between 2004 and 2013 from the National Cancer Database (NCDB). Patients were categorized based on the interval between chemoradiation and surgery (0 - ?3 weeks, 3 - ?6 weeks, 6 - ?9 weeks, and 9 - ?12 weeks). Patients with stage IIIB and other clinical stages were excluded from this study. Overall survival (OS) was examined using Kaplan-Meier method and log-rank tests and bootstrapped Cox proportional hazards model was used to determine significant contributors to OS.

The results of the study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), showed that of the 1,623 NSCLC patients identified with clinical stage IIIA, T1-3 N2 disease, 7.9% underwent surgery at 0 - ?3 weeks, 50.5% underwent surgery 3 - ?6 weeks, 31.9% underwent surgery 6 - ?9 weeks, and 9.6% underwent surgery 9 - ?12 weeks after NCRT. In the univariate analysis, there was no significant difference in OS between the patients that underwent surgery at 0 - ?3 weeks or 3 - ?6 weeks. Decreasing OS was observed in patients that underwent surgery at 6 - ?9 weeks and patients that underwent surgery 9 - ?12 weeks fared significantly worse than those patients that had surgery at 0 - ?3 weeks after NCRT. Multivariate analysis, which accounted for patients receiving lobectomy verses pneumonectomy, showed no significant difference in OS for patients who underwent surgery within 6 weeks of NCRT. However, a significant decrease in OS was observed in patients who had surgery 6 - ?9 weeks (HR: 1.33, 95% CI: 1.01-1.76, P=0.043) and 9 - ?12 weeks (HR: 1.44, 95% CI: 1.04-2.01, P=0.030) after NCRT.

The authors comment that, "The results of our study suggest that waiting greater than 6 weeks to have surgery after NCRT may negatively impact both perioperative mortality and OS. This finding concurs with prior data that recommend an ITS following NCRT of less than 8 weeks. Minimizing the time between NCRT and surgery is thought to improve outcomes because it reduces the risks associated with operating in the presence of radiation pneumonitis. Although radiation may affect surgical outcomes anywhere between 3 and 12 weeks, it is particularly troublesome at the tail end of that interval when a patient is at highest risk for the development of fibrosis, narrowing of the pulmonary vessels, microvascular thrombosis, and collagen deposition by fibroblasts into the interstitium, increasing the risk for postoperative complications."
Co-authors Frank Detterbeck, Daniel Boffa, Roy Decker, and Anthony Kim are members of IASLC.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit for more information.

Written by: Jacinta Wiens, PhD, 720-598-1941;

Media Contact: Becky Bunn, 720-254-9509;

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
More Lung Cancer News and Lung Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at